Amarin Corp Plc (AMRN)

[Whalatane]

O ...well the business case for at least Covid is pretty obvious
.

A 2020 study by the Kaiser Family Foundation found that the average cost of COVID-19 hospitalization for people with private health insurance was $41,611.
This includes the cost of the hospital stay, as well as the cost of medications and other treatments.

If Vascepa reduced Covid hospitalization at Kaiser facilities ...Kaiser obviously would save a lot of $

For CV outcomes theres a similar case. If Vascepa reduces the need for revascularisation ......Kaiser saves $
Why does Kaiser need to save $ ?
Because they run as a non profit .
If they start running up huge expenses ...those expenses eventually get paid by Kaiser members thru higher co pays , monthly charges etc .
Why does that matter ?
Because if my cost to stay with Kaiser skyrockets ...I and many others will switch to less expensive health insurers

Kiwi